: iStockAnalyst.com Symbols Feed

VICL, DNDN, BKD, RINO, ASPM, IFLO, HITK, AFFX: Seven Bullish Healthcare Stocks

Mon, 12 Oct 2009 15:35:00 GMT

Stocks in medical sector have been in the limelight for quite some time. Yesterday, I researched over 400 stocks in the medical sector.[More...]

Rally Rolls On

Mon, 03 Aug 2009 22:41:59 GMT

The indices had another strong start to the week with another strong gap up at the opening on very positive futures. They then backed and filled, retested early lows and then rallied steadily to mid-afternoon when they reached their peaks for the day. They pulled back into the last hour, but in the last 15-mintues snapped back sharply to close near the highs for the day on the Nasdaq 100 and not far from them on the S&P 500. Net on the day the Dow gained 114.95 to 9286.56, just 12 points off its high. The S&P 500 was up 15.15 to 1002.63, closing over 1000 for the first time since November. That was less than a point from its highs. The Nasdaq 100 advanced 24.76 to 1628.12, just pennies from its high. Advance-declines were 5 to 1 positive on New York and 2/1/2 to 1 positive on Nasdaq. Up/down volume was about 7 1/2 to 1 positive on New York on total volume of just under 1.2[More...]

Affymetrix (NASDAQ:AFFX): Color On Quarter; Upgraded To Overweight At Piper Jaffray

Thu, 23 Jul 2009 13:23:06 GMT

Affymetrix (NASDAQ:AFFX) is getting lots of commentary followin better-than-expected Q2 results: - Piper Jaffray is upgrading their rating to Overweight from Neutral and raising their target to $11 (prev. $5) Firm notes the upgrade reflects a favorable valuation, improving operational metrics and favorable revenue mix. They note the management is successfully restructuring the company's manufacturing cost base (and now turning their attention to operating expenses), the valuation (currently trading at 1.0x 2010 EV/Rev estimate) and the changing mix of business away from markets where they are less competitive (i.e. GWAS) and shifting resources toward markets that benefit Affy's products (such as pharmacogenomics). At this point, Piper believes it is far too premature[More...]

Which Healthcare Companies Could Benefit From Obama's Government Healthcare Plan?

Mon, 02 Mar 2009 17:52:52 GMT

As promised during his election campaign, President Obama seems to be swiftly acting on the US healthcare reform.[More...]

Phoenix Rising?

Tue, 24 Feb 2009 04:47:00 GMT

With the US equity market averages either probing or breaking down through their November lows, is it time to buy Phoenix stocks? Others have picked up on that theme, with the latest being a Minyanville article on buying beaten up stocks. With that in mind, I screened the US market for stocks with the following characteristics: Stock price between $1 and $5 (low-priced stocks)Down at least 80% from a year ago (beaten up)Market cap of $100 million or more (were once "real" companies)Net insider buying in the last six months (some downside protection from insider activity) This screen gives us a list of low-priced[More...]

Illumina: Shining Bright

Wed, 04 Feb 2009 19:46:00 GMT

Genetic analysis company Illumina Inc. (NASDAQ: ILMN), late on Tuesday, announced impressive results that sent its stock soaring over 20%.[More...]

Illumina (ILMN) Continues to Execute

Wed, 04 Feb 2009 15:37:00 GMT

Illumina (ILMN) has been a holding with us for most of the life of the fund; this was beaten bloody and senseless late in 2008 although fundamentally nothing went wrong. Which is why this stock market is so difficult - owning stocks on fundamentals is not working for the vast majority of names. The company reported another good quarter last night and the beat goes on. Compared to competitor Affymetrix (AFFX) the company is hitting home run after home run. Yet you would of lost a similar amount of money owning each for much of the past year. Illumina Inc ([More...]

New Preventive Medicine Index

Sun, 25 Jan 2009 18:49:00 GMT

One of the major reasons behind Pfizer's (PFE) interest in acquiring Wyeth (WYE) is the latter's focus on products outside of traditional pharmaceuticals – with 60% of Wyeth's revenue from last year derived from biological therapeutics and vaccines. It remains to be seen what happens to Wyeth's proposed deal to acquire Dutch vaccine maker Crucell (CRXL); however since it is much smaller (around $1B) and focuses on the development of vaccines, Pfizer would likely be interested in both companies[More...]

A New Emerging Diagnostics Index

Fri, 26 Dec 2008 15:27:00 GMT

The accompanying table (click to enlarge) includes 39 companies in the ETF Innovators (ETFI) Emerging Diagnostics Index of U.S.-listed stocks with market caps of $10-$200M. The index includes diabetes care device makers such as DexCom (DXCM), personalized medicine lab service providers such as Clarient (CLRT), clinical diagnostic test developers such as OraSure (OSUR), diagnostic imaging service providers such as Virtual Radiologic (VRAD), diagnostic equipment makers such as Vision Sciences (VSCI), and genetic[More...]

Ten Under The Radar Small And Micro-Cap Value Stocks (Healthcare)

Sun, 16 Nov 2008 18:15:00 GMT

The accompanying table presents 10 small and micro-cap companies from a variety of industries which are trading at value parameters, with average valuations for the group of 0.54X trailing 12-month sales, 0.44X enterprise value to sales, 0.88X book value, and 8.7X trailing 12-month earnings. The iShares Russell 2000 Small-Cap Value ETF (IWN) has lost about 39% in the past year and serves as a useful ETF benchmark comparison for these companies. Healthcare – Diagnostics: Home Diagnostics (HDIX) is a maker of blood glucose monitoring systems and supplies under the TRUE and Prestige[More...]

Gene-testing startup's study responds to critics

Thu, 09 Oct 2008 04:53:00 GMT

SAN FRANCISCO - A Silicon Valley gene-testing startup is responding to criticism that the tests could spur bad health-care choices by teaming up for a broad study of how the results affect behavior.
Negative results, critics say, could inspire others to be less cautious than they should be about lifestyle choices or preventative care.
Scripps hopes to report its first findings in April or May, about three months after participants receive their DNA test results, Topol said.

: iStockAnalyst.com Symbols Feed

VICL, DNDN, BKD, RINO, ASPM, IFLO, HITK, AFFX: Seven Bullish Healthcare Stocks

Rally Rolls On

Affymetrix (NASDAQ:AFFX): Color On Quarter; Upgraded To Overweight At Piper Jaffray

Which Healthcare Companies Could Benefit From Obama's Government Healthcare Plan?

Phoenix Rising?

Illumina: Shining Bright

Illumina (ILMN) Continues to Execute

New Preventive Medicine Index

A New Emerging Diagnostics Index

Ten Under The Radar Small And Micro-Cap Value Stocks (Healthcare)

Gene-testing startup's study responds to critics

BioInformatics, LLC New Report - New Media Marketing Channels: Creating Effective Online Life Science Promotional Videos

The NIAID-Supported Pathogen Functional Genomics Resource Center at the J. Craig Venter Institute Offers New Affymetrix Array for Faster Identification of E. Coli and Shigella

Affymetrix Reports Second Quarter 2009 Results

Affymetrix Reports Second Quarter 2009 Results ; -- Company Reports Total Revenue of $81.6 Million and Net Income of $7.3 Million --

Affymetrix to Host Conference Call on July 22, 2009 to Announce Second Quarter 2009 Results

Affymetrix to Webcast Annual Meeting of Shareholders

Key Milestones to Improve Operating Leverage Achieved Ahead of Schedule

Affymetrix, Inc. (AFFX) President and Chief Executive Officer to Ring the NASDAQ Stock Market Opening Bell

Affymetrix Chief Medical Officer to speak at AAAS on Personalized Medicine

Entrepreneur Magazine Picks Affymetrix as One of Top 100 Companies to Watch

Form 4 DIEKMAN JOHN D For: Oct 09 (10K)

Form 4 DIEKMAN JOHN D For: Aug 04 (10K)

Form 4 AFFYMETRIX INC For: Aug 20 Filed by: RUNKEL JOHN F JR (10K)

Form 4 FODOR STEPHEN P A For: Aug 20 (10K)

Form 4 BATTY JOHN For: Aug 20 (10K)

Form 4 King Kevin M For: Aug 20 (10K)

Form 4 BATTY JOHN For: Jun 27 (10K)

Form 4 King Kevin M For: Jun 27 (10K)

Form 4 FODOR STEPHEN P A For: Jun 27 (10K)

Form 4 BATTY JOHN For: Jun 18 (10K)